Hintringer, K. (2009): Cetuximab (Erbitux®) in EGFR-expressing Non-Small Cell Lung Cancer. DSD: Horizon Scanning in Oncology 02.
|PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader|
The efficacy of Cetuximab (Erbitux®), a human monoclonal antibody designed to specifically direct against the epidermal growth factor receptor on the surface of tumour cells, in patients with Non-Small Cell Lung Cancer has recently been examined in phase II and III trials.
Minor increases in progression free survival and overall survival were found, if cetuximab was added to chemotherapy. The safety examination of adding cetuximab to platinum-based double-agent chemotherapy showed higher toxicity rates and more serious adverse events in the cetuximab arm than in the control arm.
Before market access of cetuximab for the treatment of patients with non-small cell lung cancer, benefits and risks of the therapy have to be weighed carefully.
|Item Type:||DSD: Horizon Scanning in Oncology|
|Keywords:||Lung cancer, non-small cell, cetuximab, Erbitux, epidermal-growth-factor-receptor, EGFR|
|Subjects:||QZ Pathology > QZ 200-380 Neoplasms.Cysts|
WF Respiratory system
|Series Name:||DSD: Horizon Scanning in Oncology 02|
|Deposited on:||19 Oct 2009 10:03|
|Last Modified:||28 Jan 2010 17:13|
Repository Staff Only: item control page